- ISIN
- US23954D1090
- CUSIP
- 23954D109
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- May 27, 2021
Highlights
- EPS (TTM)
- -$1.47
- Total Revenue (TTM)
- $133.67M
- Gross Profit (TTM)
- $119.56M
- EBITDA (TTM)
- -$141.73M
- Year Range
- $5.64 - $21.53
- Target Price
- $26.00
- ROA (TTM)
- -29.88%
- ROE (TTM)
- -34.40%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
DAWN Performance Chart
Loading charts...
Returns By Period
Day One Biopharmaceuticals, Inc.
- 1D
- —
- 1M
- —
- YTD
- —
- 6M
- —
- 1Y
- —
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 0.13%
- 1M
- 5.25%
- YTD
- 11.16%
- 6M
- 11.43%
- 1Y
- 28.20%
- 3Y*
- 21.12%
- 5Y*
- 12.66%
- 10Y*
- 13.75%
DAWN Monthly Returns History
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 19.74% | -5.02% | 102.26% | 0.42% | 131.01% | ||||||||
| 2025 | -2.37% | -26.76% | -12.47% | -1.89% | -17.99% | 1.88% | 3.23% | 11.92% | -6.13% | 5.53% | 27.55% | -1.79% | -26.44% |
| 2024 | 3.08% | 11.16% | -1.26% | 3.51% | -22.40% | 3.84% | 3.85% | -3.28% | 0.65% | 5.67% | -5.37% | -9.05% | -13.22% |
| 2023 | 1.16% | -15.39% | -27.42% | -7.26% | 7.26% | -10.23% | 10.89% | 1.89% | -9.04% | -3.59% | -2.11% | 26.08% | -32.16% |
| 2022 | -12.46% | -7.39% | -27.38% | -14.11% | -27.00% | 187.78% | -4.30% | 37.13% | -14.73% | 5.54% | 0.43% | 1.37% | 27.72% |
| 2021 | -8.50% | -3.88% | 4.17% | 17.33% | -14.73% | 2.99% | -24.84% | -8.27% | -34.92% |
Benchmark Metrics
Day One Biopharmaceuticals, Inc. has an annualized alpha of 24.36%, beta of 0.70, and R2 of 0.02 versus S&P 500 Index. Calculated based on daily prices since May 28, 2021.
- This stock tended to rise when S&P 500 Index fell (downside capture of -48.50%), but participation in market rallies was also limited (-26.10%) - a profile typical of counter-cyclical assets.
- R2 of 0.02 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 24.36%
- Beta
- 0.70
- R²
- 0.02
- Upside Capture
- -26.10%
- Downside Capture
- -48.50%
Return for Risk
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Day One Biopharmaceuticals, Inc. (DAWN) and compare them to S&P 500 Index.
Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Day One Biopharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Day One Biopharmaceuticals, Inc. was 79.51%, occurring on May 27, 2022. The portfolio has not yet recovered.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
Bear market2022 | -79.51%May 2022 | 8mo 27d | — | 4y 9moSep 2021 - now |
2021 bear market2021 | -26.61%Jun 2021 | 6d | 2mo 4d | 2mo 10dMay 2021 - Aug 2021 |
2021 correction2021 | -17.60%Aug 2021 | 2d | 12d | 14dAug 2021 - Aug 2021 |
2021 pullback2021 | -0.76%Aug 2021 | 0s | 4d | 4dAug 2021 - Aug 2021 |
Drawdown Indicators
| DAWN | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | — | -56.78% | — |
Max Drawdown (1Y)Largest decline over 1 year | — | -9.10% | — |
Max Drawdown (3Y)Largest decline over 3 years | — | -18.90% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | — | 0.00% | — |
Average DrawdownAverage peak-to-trough decline | — | -10.72% | — |
Ulcer IndexDepth and duration of drawdowns from previous peaks | — | 1.97% | — |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Day One Biopharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Day One Biopharmaceuticals, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for DAWN relative to other companies in the Biotechnology industry. Currently, DAWN has a P/S ratio of 16.6. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with DAWN
Add Day One Biopharmaceuticals, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with DAWN